CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Lisata Therapeutics, Inc - LSTA CFD

2.87
1.03%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024846 %
Charges from full value of position ($-4.72)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024846%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002624 %
Charges from full value of position ($0.50)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002624%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 2.9
Open 2.88
1-Year Change 40.49%
Day's Range 2.87 - 2.88
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 24, 2024 2.87 -0.02 -0.69% 2.89 2.89 2.87
Oct 23, 2024 2.90 0.02 0.69% 2.88 2.91 2.88
Oct 22, 2024 2.89 -0.07 -2.36% 2.96 3.09 2.89
Oct 21, 2024 2.96 -0.03 -1.00% 2.99 3.07 2.96
Oct 18, 2024 2.93 0.01 0.34% 2.92 2.93 2.92
Oct 17, 2024 2.92 -0.03 -1.02% 2.95 2.95 2.89
Oct 16, 2024 2.90 0.01 0.35% 2.89 2.93 2.89
Oct 15, 2024 2.90 0.01 0.35% 2.89 2.93 2.89
Oct 14, 2024 2.90 -0.02 -0.68% 2.92 2.92 2.89
Oct 11, 2024 2.96 -0.01 -0.34% 2.97 3.03 2.91
Oct 10, 2024 2.96 0.07 2.42% 2.89 3.07 2.89
Oct 9, 2024 2.92 0.10 3.55% 2.82 3.07 2.82
Oct 8, 2024 2.89 0.07 2.48% 2.82 2.97 2.82
Oct 7, 2024 2.92 -0.04 -1.35% 2.96 2.96 2.92
Oct 4, 2024 3.00 0.09 3.09% 2.91 3.04 2.91
Oct 3, 2024 2.93 0.23 8.52% 2.70 2.93 2.69
Oct 2, 2024 2.86 -0.03 -1.04% 2.89 2.91 2.75
Oct 1, 2024 2.90 -0.02 -0.68% 2.92 2.99 2.76
Sep 30, 2024 2.96 0.05 1.72% 2.91 2.99 2.84
Sep 27, 2024 2.85 -0.04 -1.38% 2.89 2.89 2.84

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lisata Therapeutics, Inc Company profile

About Caladrius Biosciences Inc

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).

Financial summary

BRIEF: For the 39 weeks ended 30 September 2021, Caladrius Biosciences Inc revenues was not reported. Net loss increased from $2.7M to $20.7M. Higher net loss reflects Research and development increase from $6.1M to $12.9M (expense), Other Selling, gen & admi increase of 18% to $7.7M (expense), Stock-based Compensation in R&D increase from $239K to $643K (expense).

Equity composition

Common Stock $.001 Par, 03/11, 500M auth., 78,564,199 issd. reverse acquisition with Fidelity Medical Services Inc. 08/06, Name changed from Phase III Medical, Inc. 08/07, Exchange changed from OTC to AMEX. 08/07, 1-for-10 reverse stock consolidation. Pref Stock B $0.1 Par, 10,000 issd., 07/13, 1-for-10 reverse sotck split.

Industry: Biotechnology & Medical Research (NEC)

110 Allen Road
Second Floor
07920

News

US elections: Trump leads the polls, but tariff talk spooks investors

As the US elections get closer we look at how Trump’s tariff plans could affect markets.

15:02, 22 October 2024

Gold markets to trade

Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.

08:00, 21 October 2024

US earnings seasons off to a solid start as focus shifts to tech giants

The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.

14:31, 17 October 2024

ECB Preview: cooling growth and inflation call for another rate cut

Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.

12:41, 16 October 2024

Australian labour force data forecast to reveal stable jobs market

Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.

07:41, 15 October 2024

Applying fundamental and technical strategies to Gold Trading

Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.

08:00, 14 October 2024

S&P 500 expected to deliver modest earnings growth in Q3

Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.

12:40, 11 October 2024

People also watch

Oil - Crude

70.66 Price
+0.500% 1D Chg, %
Long position overnight fee 0.0094%
Short position overnight fee -0.0314%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.53 Price
-1.240% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,720.99 Price
-0.560% 1D Chg, %
Long position overnight fee -0.0176%
Short position overnight fee 0.0094%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

20,298.10 Price
+0.300% 1D Chg, %
Long position overnight fee -0.0248%
Short position overnight fee 0.0026%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading